Radicle Clarity: A Study of Health and Wellness Products on Mental Clarity and Health Outcomes

Launched by RADICLE SCIENCE · Dec 7, 2022

Keywords

ClinConnect Summary

This is a randomized, blinded, placebo-controlled study conducted with adult participants, age 21 and older and residing in the United States.

Eligible participants will (1) endorse a desire for better concentration, (2) indicate an interest in taking a health and wellness product to potentially help their concentration, and (3) express acceptance in taking a product and not knowing its formulation until the end of the study.

Participants with known liver or kidney disease, heavy drinkers, and those who report they are pregnant, trying to become pregnant, or breastfeeding will be excluded...

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Adults, 21 years of age and older at the time of electronic consent, inclusive of all ethnicities, races, genders and/or gender identities
• • Resides in the United States
• • Endorses better concentration as a primary desire
• • Selects concentration and/or looking to improve their concentration as a reason for their interest in taking a health and wellness product
• • Expresses a willingness to take a study product and not know the product identity (active or placebo) until the end of the study
• Exclusion Criteria:
• • Reports being pregnant, trying to become pregnant, or breastfeeding
• • Unable to provide a valid US shipping address and mobile phone number
• • The calculated validated health survey (PRO) score during enrollment represents less than mild impairment or severity
• • Reports a diagnosis of liver or kidney disease
• • Reports being a heavy drinker (defined as drinking 3 or more alcoholic beverages per day)
• • Unable to read and understand English
• • Reports current enrollment in a clinical trial
• • Lack of reliable daily access to the internet
• • Reports current or recent (within 3 months) use of chemotherapy or immunotherapy
• • Reports taking medications with a known moderate or severe interaction with any of the active ingredients studied or a substantial safety risk: Anticoagulants, a medication that warns against grapefruit consumption, corticosteroids at doses greater than 5 mgs per day, oral anti-infectives (antibiotics, antifungals, antivirals) to treat an acute infection, antipsychotics, or MAOIs (monoamine oxidase inhibitors)
• • Reports a diagnosis of heart disease when a known contraindication exists for any of the active ingredients studied: NYHA (New York Heart Association) Class III or IV congestive heart failure, Atrial fibrillation, Uncontrolled arrhythmias

Trial Officials